Novartis Attributes Discovery of Novel Cancer Inhibitor to its 'Genesis' Generative Biology Platform
Novartis revealed that its proprietary AI, 'Genesis', independently hypothesized, simulated, and identified a promising new molecule for treating aggressive forms of lung cancer, a process that took only 45 days. This breakthrough validates massive R&D investment in AI and fundamentally changes the economics and speed of drug discovery, creating a new competitive benchmark for the entire pharmaceutical and biotech industries.